)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Cue Biopharma
Cue Biopharma (CUE) investor relations material
Cue Biopharma Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary14 May, 2026
Executive summary
Lead asset CUE-221, a novel anti-IgE antibody, is in Phase 2 for allergic diseases with an exclusive license agreement signed in April 2026.
CUE-401, a bifunctional IL-2 and TGF-B program for autoimmune disease, is IND-ready with Phase 1 planned by end of 2026.
CUE-501 is partnered with Boehringer Ingelheim (BI) for B cell depletion in autoimmune diseases.
Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO, and Board Director in April 2026 to drive clinical-stage growth.
Substantial doubt exists about ability to continue as a going concern beyond Q1 2027 without additional capital.
Financial highlights
Collaboration revenue for Q1 2026 was $5.7M, up from $0.4M in Q1 2025, mainly from the Boehringer Ingelheim collaboration.
Net loss for Q1 2026 was $5.2M, a significant improvement from $12.3M loss in Q1 2025.
Cash and cash equivalents at March 31, 2026 were $16.4M, with an additional $30M raised and $7.5M milestone received post-quarter.
Operating expenses decreased to $11.0M in Q1 2026 from $12.7M in Q1 2025, mainly due to lower R&D costs.
Research and development expenses decreased to $6.9M from $8.5M year-over-year.
Outlook and guidance
Cash runway, including recent financing and BI milestone, expected to fund operations into Q1 2027.
IND amendment for CUE-221 in food allergy planned for H2 2026; Phase 2b trial to follow pending China study results.
Results from China Phase 2 study in Chronic Spontaneous Urticaria expected in H2 2026.
IND submission for CUE-401 expected in H2 2026, with Phase 1 study initiation by year-end 2026.
Additional capital will be needed to continue operations and development programs beyond this period.
CUE-221 Phase 2b trial dependency on CSU results
Drivers for the Q1 2026 R&D expense reduction
Remediation of the going concern determination
CUE-221 license financial terms and territories
Terms of the April 2026 private placement
Recent BI collaboration milestone and payment
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cue Biopharma
- Shareholders to vote on major share issuance, new incentive plan, and meeting adjournment authority.CUE
Proxy filing12 May 2026 - All proposals, including a reverse stock split, were approved at the virtual meeting.CUEAGM 202613 Apr 2026
- Advancing to Phase 1, the bifunctional therapy targets autoimmune diseases with strong preclinical data.CUER&D Day 202613 Apr 2026
- Director resignation leads to interim CEO appointment and board size reduction.CUEProxy filing27 Mar 2026
- Biotech seeks up to $300M in securities amid going concern risk and ongoing capital needs.CUERegistration Filing17 Mar 2026
- Q4 2025 revenue soared on ImmunoScape deal, with CUE-401 advancing and liquidity improved.CUEQ4 202516 Mar 2026
- Key votes include director elections, auditor ratification, and a reverse stock split to support Nasdaq compliance.CUEProxy Filing16 Mar 2026
- Proxy seeks approval for director elections, auditor, executive pay, and a reverse stock split.CUEProxy Filing6 Mar 2026
- Obesity phase III trials advance, with strong oral efficacy and new maintenance strategies underway.CUECantor Global Healthcare Conference 20253 Feb 2026
Next Cue Biopharma earnings date
Q2 202612 Aug, 2026
Cue Biopharma
Next Cue Biopharma earnings date
Q2 202612 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage